Dr. Agarwals Health Care Ltd
P&L
Quarterly Consolidated
vs Q4 FY25
Dr. Agarwals Health Care Ltd Reports 22.3% YoY Increase in Total Income for Q1 FY2026
12 Aug 2025 · 12 Aug 2025, 06:02 pm
Summary
Dr. Agarwal’s Health Care Limited, India’s largest eye care service chain, reported a 22.3% YoY increase in total income for the quarter ended June 30, 2025. The company's EBITDA grew by 28.9% YoY to INR 141 Crores and PAT grew by 108.9% YoY to INR 38 Crores. The company performed 78,882 surgeries in 3M FY2026, a growth of 16.0% YoY.
Key Highlights
- 1
Network stands at 249 facilities, with 13 new centers added during the quarter
- 2
Performed 78,882 surgeries in 3M FY2026, growth of 16.0% YoY
- 3
Total Income of INR 501 Crores; growth of 22.3% YoY
- 4
Revenue from Operations of INR 487 Cr; growth of 20.8% YoY
- 5
EBITDA of INR 141 Cr, growth of 28.9% YoY with EBITDA margins of 28.2%
- 6
Profit after Tax of INR 38 Cr, growth of 108.9% YoY with profit after tax margins of 7.6%
Management Comments
Dr. Adil Agarwal
CEO, Dr. Agarwal’s Health Care Limited
The first quarter of the new fiscal year has started with a robust performance. We are pleased to report the highest-ever revenue on a quarterly basis, with profit margins sustaining at high levels. Total income for the quarter stood at %501 crore, a growth of 22.3% over the same period last year, driven by healthy growth across our network. Our EBITDA rose by 28.9% to 2141 crore, underscoring our focus on operational efficiency and cost discipline. Profit after tax more than doubled to 338 crore, up 108.9% year-on-year. Operationally, our network grew to 249 eye care facilities as of June 30, 2025, with 13 new additions during the quarter. We also marked our strategic entry into the Delhi market, opening our first centre in the capital to strengthen our presence in North India. We served over 7 lakh+ patients and performed c.79,000 surgeries, supported by our team of 850+ doctors. This scale and expertise allow us to deliver advanced, high-quality eye care at greater reach than ever before. We remain committed to expanding our footprint, investing in advanced technologies, and delivering superior clinical outcomes to our patients.
Informational and educational content only. Not investment advice.